GetTopicDetailResponse(id=76d4e09219f, topicName=病毒學(xué)應(yīng)答率, introduction=病毒學(xué)應(yīng)答率, content=null, image=null, comments=4, allHits=730, url=https://h5.medsci.cn/topic?id=70921, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=30391, tagList=[TagDto(tagId=30391, tagName=病毒學(xué)應(yīng)答率)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1799603, encodeId=03d21e9960334, content=<a href='/topic/show?id=76d4e09219f' target=_blank style='color:#2F92EE;'>#病毒學(xué)應(yīng)答率#</a>, objectTitle=NEJM：Ledipasvir/Sofosbuvir治療提高了HIV-1/HCV共感染患者的持續(xù)病毒學(xué)應(yīng)答率, objectType=article, longId=53683, objectId=f61b53683e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f61b53683e0, replyNumber=0, likeNumber=78, createdTime=2015-10-23, rootId=0, userName=ylz8403, userId=3fce464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f61b53683e0, moduleTitle=NEJM：Ledipasvir/Sofosbuvir治療提高了HIV-1/HCV共感染患者的持續(xù)病毒學(xué)應(yīng)答率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f61b53683e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1799604, encodeId=74201e99604d5, content=<a href='/topic/show?id=76d4e09219f' target=_blank style='color:#2F92EE;'>#病毒學(xué)應(yīng)答率#</a>, objectTitle=NEJM：Sofosbuvir和Velpatasvir治療HCV感染有較高的病毒學(xué)應(yīng)答率, objectType=article, longId=58934, objectId=42b75893460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42b75893460, replyNumber=0, likeNumber=80, createdTime=2016-07-14, rootId=0, userName=ylz8403, userId=3fce464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42b75893460, moduleTitle=NEJM：Sofosbuvir和Velpatasvir治療HCV感染有較高的病毒學(xué)應(yīng)答率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=42b75893460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1799602, encodeId=47a51e99602f5, content=<a href='/topic/show?id=76d4e09219f' target=_blank style='color:#2F92EE;'>#病毒學(xué)應(yīng)答率#</a>, objectTitle=EASL 2014：NUCs與IFN聯(lián)合序貫治療提高慢乙肝病毒學(xué)應(yīng)答率, objectType=article, longId=33344, objectId=40aa3334452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40aa3334452, replyNumber=0, likeNumber=100, createdTime=2015-01-25, rootId=0, userName=ylz8403, userId=3fce464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40aa3334452, moduleTitle=EASL 2014：NUCs與IFN聯(lián)合序貫治療提高慢乙肝病毒學(xué)應(yīng)答率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=40aa3334452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1799601, encodeId=46b21e99601f8, content=<a href='/topic/show?id=76d4e09219f' target=_blank style='color:#2F92EE;'>#病毒學(xué)應(yīng)答率#</a>, objectTitle=J Hepatol：胰島素抵抗（IR）降低丙肝持續(xù)病毒學(xué)應(yīng)答率, objectType=article, longId=3835, objectId=97e0383515, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97e0383515, replyNumber=0, likeNumber=142, createdTime=2012-07-18, rootId=0, userName=ylz8403, userId=3fce464, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97e0383515, moduleTitle=J Hepatol：胰島素抵抗（IR）降低丙肝持續(xù)病毒學(xué)應(yīng)答率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=97e0383515)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
